Sofia Chiatamone Ranieri

Sofia Chiatamone Ranieri

Auto-generated profile, based on publicly available information

Sofia Chiatamone Ranieri

Pathology Unit, Department of Services, AUSL 04 Teramo, 64100 Teramo, Italy

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 October 2017 in BMC Cancer
Verified
Journal Article
Open access
PDF file
PBPaola Ballotari
Paola Ballotari
MVMassimo Vicentini
Massimo Vicentini
VMValeria Manicardi
Valeria Manicardi
MGMarco Gallo
Marco Gallo
SRSofia Chiatamone Ranieri
Sofia Chiatamone Ranieri
PRPaolo Giorgi Rossi
Paolo Giorgi Rossi
Aim of this study was to compare cancer incidence in populations with and without diabetes by cancer site. Furthermore, we aimed at comparing excess risk of cancer according to diabetes type, diabetes duration and treatment, the latter as regards Type 2 diabetes. By use of the Reggio Emilia diabetes registry we classified the resident population aged 20–84 at December 31st 2009 into two groups: with and without diabetes. By linking with the cancer registry we calculated the 2010–2013 cancer incidence in both groups. The incidence rate ratios (IRR) by cancer site, type of diabetes, diabetes duration, and as concerns Type 2 diabetes, by treatment regimen were computed using Poisson regression model and non-diabetic group as reference. The cohort included 383,799 subjects without diabetes and 23,358 with diabetes. During follow-up, we identified 1464 cancer cases in subjects with diabetes and 9858 in the remaining population. Overall cancer incidence was higher in subjects with diabetes than in those without diabetes (IRR = 1.22, 95%CI 1.15–1.29), with similar results focusing on subjects with at least 2-year diabetes duration. Cancer sites driving overall increased risk were liver, pancreas, Colon rectum, and bladder in both sexes, corpus uteri for females. There was also suggestion of an increased risk for kidney cancer in females and a decreased risk for prostate cancer. Excess risk was found in patients with Type 2 diabetes, more marked among insulin users, especially with combined therapy. We observed an increasing risk for diabetes duration up to 10 years from diagnosis (IRR = 1.44, 95%CI 1.29–1.61) and a subsequent decrease to moderate-higher risk (IRR = 1.15, 95%CI 1.04–1.30). Our study indicates that the strength of association depends on specific cancer site. Insulin, monotherapy or combined therapy, per se or as an indication of poor blood glucose control, in addition to diabetes duration, may play a role in the association of diabetes and cancer.

1 January 2015 in International Journal of Endocrinology
Verified
Journal Article
Open access
PDF file
PBPaola Ballotari
Paola Ballotari
SRSofia Chiatamone Ranieri
Sofia Chiatamone Ranieri
FLFerdinando Luberto
Ferdinando Luberto
SCStefania Caroli
Stefania Caroli
MGMarina Greci
Marina Greci
VMValeria Manicardi
Valeria Manicardi
The objective of this study is to assess the impact of diabetes on cardiovascular mortality, focusing on sex differences. The inhabitants of Reggio Emilia province on December 31, 2009, aged 20–84 were followed up for three years for mortality. The exposure was determined using Reggio Emilia diabetes register. The age-adjusted death rates were estimated as well as the incidence rate ratios using Poisson regression model. Interaction terms for diabetes and sex were tested by the Wald test. People with diabetes had an excess of mortality, compared with nondiabetic subjects (all cause: IRR = 1.68; 95%CI 1.60–1.78; CVD: IRR = 1.61; 95%CI 1.47–1.76; AMI: IRR = 1.59; 95%CI 1.27–1.99; renal causes: IRR = 1.71; 95%CI 1.22–2.38). The impact of diabetes is greater in females than males for all causes (P=0.0321) and for CVD, IMA, and renal causes. Further studies are needed to investigate whether the difference in cardiovascular risk profile or in the quality of care delivered justifies the higher excess of mortality in females with diabetes compared to males.

12 March 2023 in Cancers
Verified
Journal Article
Open access
PDF file
AIAzzurra Irelli
Azzurra Irelli
SRSofia Chiatamone Ranieri
Sofia Chiatamone Ranieri
DGDaniela Di Giacomo
Daniela Di Giacomo
SMSara Malatesta
Sara Malatesta
LPLeonardo Valerio Patruno
Leonardo Valerio Patruno
KCKatia Cannita
Katia Cannita
Molecular tumor boards (MTBs) are multidisciplinary groups that combine molecular and clinical data from cancer patients in order to formulate treatment recommendations for precision medicine. To date, there is insufficient data to support the use of singleplex or next-generation sequencing (NGS) technologies to select first-line therapy for patients with metastatic breast cancer (MBC), but considering the high number of level II alterations, according to the ESMO scale for clinical actionability of molecular targets (ESCAT), it is suggested to include patients in molecular screening programs in order to be able to offer targeted therapies for specific genomic alterations. This article aims at reviewing the most recent literature related to the most used methodologies/approaches for molecular diagnostics and variants’ classification, summarizing the internationally published molecular screening studies in support of MTB activity and, in the end, discussing MTBs’ current position and role in Italy, the number of which is increasing, also thanks to the thrust of institutions.

12 November 2019 in Case Reports in Hematology
Verified
Journal Article
Open access
PDF file
SRSofia Chiatamone Ranieri
Sofia Chiatamone Ranieri
Stefania TrasartiStefania Trasarti
Stefania Trasarti
MAMaria Antonietta Arleo
Maria Antonietta Arleo
LBLuisa Bizzoni
Luisa Bizzoni
LBLivia Bonanni
Livia Bonanni
RFRobin Foà
Robin Foà
Thymoma is an uncommon slowly growing neoplasm. It usually presents with paraneoplastic syndromes including the immunodeficiency syndrome called Good syndrome and hematological disorders. Pure red cell aplasia is a well-recognized complication of thymoma, and aplastic anemia is very rare in association with GS. We report a case of GS in a heavily treated patient with stage IV thymoma associated with a pure red cell aplasia and an amegakaryocytic thrombocytopenia that evolved into an AA and provide an up-to-date review of the relevant literature. This is the first case of the association of GS and AA with the coexistence of a heavily treated stage IV thymoma. The fatal outcome was not related to the progression of the thymoma, but rather to the severe infectious complications. The combination of lymphopenia and hypogammaglobulinemia typical of GS, coupled to the neutropenia, caused by bone marrow failure, was the main predisposing factor for the unfavourable outcome.

1 December 2020 in Journal of Xiangya Medicine
Verified
Journal Article
Open access
PDF file
SRSofia Chiatamone Ranieri
Sofia Chiatamone Ranieri
GLGabriella Di Leonardo
Gabriella Di Leonardo
GCGino Coletti
Gino Coletti
AMAntonella Dal Mas
Antonella Dal Mas
MBMaria Laura Brancone
Maria Laura Brancone
DDDuilio Divisi
Duilio Divisi
Background: The study evaluates the role of a combined cytological smear (CS) and cell block (CB) approaches in malignant pleural effusion (MPE), highlighting specificity and sensitivity referred to histology and the incidence of different types of malignancies. Methods: We retrospectively included 223 patients over a duration of 5 years. Pleural fluid was collected and CS together with CB were made from the fluid. Immunocytochemical (ICC) stains were applied when requested by pathologist. Histology confirmation and medical records were recorded to confirm or not cytological diagnosis. Results: The combined approach demonstrated a diagnostic accuracy of 95%, 92% sensitivity, 96% specificity, positive predictive value of 92%, negative predictive value of 96%, positive likelihood ratio of 23 and negative likelihood ratio of 0.08. Lung cancer was found to be the commonest (23 cases, 33.8%) malignant neoplasm diagnosed in the pleurae followed by breast cancer (14 cases, 20.6%), gastrointestinal cancer (7 cases, 10.3%) and mesothelioma (6 cases, 8.8%). Conclusions: In our experience the combined approach definitively has proven to have an excellent diagnostic yield in the MPE, allowing to identify the nature of malignant cells in most of patients.

22 March 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
AIAzzurra Irelli
Azzurra Irelli
LPLeonardo Valerio Patruno
Leonardo Valerio Patruno
SRSofia Chiatamone Ranieri
Sofia Chiatamone Ranieri
DGDaniela Di Giacomo
Daniela Di Giacomo
SMSara Malatesta
Sara Malatesta
KCKatia Cannita
Katia Cannita
Hereditary breast and ovarian cancer (HBOC) syndrome is responsible for approximately 10% of breast cancers (BCs). The HBOC gene panel includes both high-risk genes, i.e., a four times higher risk of BC (BRCA1, BRCA2, PALB2, CDH1, PTEN, STK11 and TP53), and moderate-risk genes, i.e., a two to four times higher risk of BC (BARD1, CHEK2, RAD51C, RAD51D and ATM). Pathogenic germline variants (PGVs) in HBOC genes confer an absolute risk of BC that changes according to the gene considered. We illustrate and compare different BC risk estimation models, also describing their limitations. These models allow us to identify women eligible for genetic testing and possibly to offer surgical strategies for primary prevention, i.e., risk-reducing mastectomies and salpingo-oophorectomies.